Clinical evaluation of paroxetine in post-traumatic stress disorder (PTSD): 52-Week, non-comparative open-label study for clinical use experience

Psychiatry and Clinical Neurosciences

Volumn 62, Issue 6, 2008, Pages 646-652

  Kim, Yoshiharu ^a   Asukai, Nozomu ^b   Konishi, Takako ^c   Kato, Hiroshi ^d   Hirotsune, Hideto ^e   Maeda, Masaharu ^f   Inoue, Hirotaka ^g   Narita, Hiroyasu ^g   Iwasaki, Masaru ^g  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^c MUSASHINO UNIVERSITY   (Japan)

^d Hyogo Institute for Traumatic Stress   (Japan)

^e OSAKA NATIONAL HOSPITAL   (Japan)

^f KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g Development and Medical Affairs Division   (Japan)

Author keywords

Japan; Paroxetine; Posttraumatic stress disorder (PTSD)

Indexed keywords

ALPRAZOLAM; BROMAZEPAM; BROTIZOLAM; CHLORPROMAZINE; CLOMIPRAMINE; ESTAZOLAM; ETIZOLAM; FLUNITRAZEPAM; FLUVOXAMINE; NITRAZEPAM; PAROXETINE; PLACEBO; TRAZODONE; ZOLPIDEM; ZOPICLONE;

ABDOMINAL PAIN; ADULT; AGGRESSION; ARTICLE; AUTOMUTILATION; CLINICAL EVALUATION; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PRACTICE; CLINICAL TRIAL; DEPRESSION; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROENTERITIS; HUMAN; HYPERTHYROIDISM; JAPANESE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MANIA; NAUSEA; OPEN STUDY; POSTTRAUMATIC STRESS DISORDER; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; STOMATITIS; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADULT; CLUSTER ANALYSIS; FEMALE; HUMANS; MALE; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME;

EID: 56849107516     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2008.01862.x     Document Type: Article

References (16)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington, DC, 1994.
2. Kim Y. Current perspectives on clinical studies of PTSD in Japan. In : Kato N, Kawata M, Pitman RK (eds). PTSD Brain Mechanisms and Clinical Implications. Springer-Verlag, Tokyo, 2007 147 154.
3. Matsuoka Y, Nishi D, Nakajima S et al. Incidence and prediction of psychiatric morbidity after a motor vehicle accident in Japan: The Tachikawa Cohort of Motor Vehicle Accident study. Crit. Care Med. 2008 36 : 74 80.
4. Foa EB, Davidson JRT, Frances A. The Expert Consensus Guideline Series: Treatment of posttraumatic stress disorder. J. Clin. Psychiatry 1999 60 (Suppl. 16 1 76.
5. Asukai N. Diagnosis, treatment, and efficacy of early intervention for PTSD. Jpn. J. Clin. Psychiatry 2000 29 : 35 40.
6. Ballenger JC, Davidson JR, Lecrubier Y et al. Consensus statement on posttraumatic stress disorder from the International Consensus Group on depression and anxiety. J. Clin. Psychiatry 2000 61 (Suppl. 5 60 66.
7. Johnson AM. Paroxetine: A pharmacological review. Int. Clin. Psychopharmacol. 1992 6 (Suppl. 4 15 24.
8. Tucker P, Zaninelli R, Yehuda R et al. Paroxetine in the treatment of chronic posttraumatic stress disorder: Results of a placebo-controlled, flexible-dosage trial. J. Clin. Psychiatry 2001 62 : 860 868.
9. Ballenger JC, Wheadon DE, Steiner M et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am. J. Psychiatry 1998 155 : 36 42.
10. Marshall RD, Beebe KL, Oldham M et al. Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. Am. J. Psychiatry 2001 158 : 1982 1988.
11. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH E8), General Considerations For Clinical Trials, 1997. Available from URL: http://www.pmda.go.jp/
12. Ministry of Health, Labour and Welfare (MHLW), Guideline for Clinical Evaluation of Anxiolytics, 1988, Iyaku-shin 1 (7).
13. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH E9), Statistical Principles For Clinical Trials, 1998. Available from URL: http://www.pmda.go.jp/
14. Miura S, Koyama T, Asai M et al. Clinical evaluation of paroxetine HCL, a selective serotonin reuptake inhibitor, in the treatment of depression of depressive episodes: Double blind, parallel group study with amitriptyline HCl. Jpn. Pharmacol. Ther. 2000 28 : 187 210.
15. Tsutsui S, Koyama T, Okuse S et al. Clinical evaluation of paroxetine HCL, a selective serotonin reuptake inhibitor, in the treatment of panic disorder. Jpn. Pharmacol. Ther. 2000 28 : 295 314.
16. Kamijima K, Murasaki M, Asai M et al. Paroxetine in the treatment of obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study in Japanese patients. Psychiatry Clin. Neurosci. 2004 58 : 427 433.